Sign In

Ted Love

President & CEO at Global Blood Therapeutics

Ted W. Love, MD is a prominent figure in the biopharmaceutical industry with extensive experience in leadership roles. Here are key details about his career and accomplishments:

Career Highlights

Dr. Love served as President and Chief Executive Officer of Global Blood Therapeutics (GBT) from June 2014 to October 2022.12 During his tenure, he led GBT from a pre-clinical startup to a global commercial company focused on developing innovative therapies for sickle cell disease.13

Previous Positions

  • Executive Vice President of Research and Development and Technical Operations at Onyx Pharmaceuticals (2010-2012)4
  • President, CEO, and Chairman of Nuvelo, Inc.1
  • Senior Vice President of Development at Theravance Biopharma1
  • Various senior management positions at Genentech, including chair of the Product Development Committee1

Current Roles

  • Chair of the Board of Directors at the Biotechnology Innovation Organization (BIO)25
  • Board member for Royalty Pharma, Structure Therapeutics, and Gilead Sciences35

Achievements and Recognition

Dr. Love is known for championing access to care, particularly for the sickle cell disease community. He received the William E. Proudford Sickle Cell Fund 2023 Distinguished Service Award and the Spirit of the Heart Health Equity Champion Award from the Association of Black Cardiologists in 2023.3

Education and Early Career

  • BA in molecular biology from Haverford College
  • MD from Yale Medical School
  • Completed residency in internal medicine and fellowship in cardiology at Massachusetts General Hospital4
  • Began his career as a member of the Department of Cardiology at Massachusetts General Hospital before transitioning to the biotech industry1

Throughout his career, Dr. Love has played a significant role in the development and approval of several important therapies, including Rituxan, Herceptin, Xolair, and Avastin during his time at Genentech.46

Highlights

Feb 5 · forbes.com
How Dr. Ted Love Sold Sickle Cell Company To Pfizer For $5.4 Billion
Feb 1 · gilead.com
Ted Love, MD, Joins Gilead Sciences' Board of Directors

Related Questions

What are Ted Love's key achievements at Global Blood Therapeutics?
How did Ted Love contribute to the development of Oxbryta?
What is Ted Love's role at Gilead Sciences?
What awards has Ted Love received for his work in biotechnology?
What was Ted Love's impact on sickle cell disease research?
Ted Love
Ted Love, photo 1
Ted Love, photo 2
Add to my network

Location

Burlingame, California